Crenessity reduces glucocorticoid dependency and improves hormone control for classic CAH.
The FDA has recently approved Crenessity (crinecerfont) for use alongside glucocorticoids in treating adults and children aged four and older with classic congenital adrenal hyperplasia (CAH), a rare genetic disorder of the adrenal glands. CAH causes cortisol deficiency and excess androgen production, requiring high glucocorticoid doses to manage hormone levels. The approved medication reduces androgen overproduction, enabling lower glucocorticoid dosages while maintaining hormone balance.
“The FDA will continue working with patients, drug companies, and health care providers to address the unmet medical needs of the rare disease community,” said Director Theresa Kehoe of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research.
Crenessity comes with the risk of adrenal crisis in patients with insufficient glucocorticoid replacement during stress. Developed by Neurocrine Biosciences, Inc., the drug received FDA’s Fast Track, Breakthrough Therapy, Orphan Drug, and Priority Review designations.
As the Lord Leads, Pray with Us…
- For prudence for FDA officials as they fast track certain medications and treatments.
- For Director Kehoe as she oversees the Division of General Endocrinology in FDA’s Center for Drug Evaluation and Research.
Sources: Food and Drug Administration
